Very early neuroglial changes have been observed to precede major vascular changes in the retina of diabetic patients and animal models. We investigated the sequence of these neuroglial changes further, in mice with alloxan-induced diabetes. Diabetes was induced by a single injection of Alloxan into C57/Bl6 mice, which subsequently received daily insulin injections. Diabetic and control animals were weighed and their blood glucose levels were determined weekly. Electroretinographic recordings and scanner laser ophthalmoscope (SLO) examinations were carried out 15 days, one month and three months after the onset of diabetes. Diabetes induction was confirmed by the presence of glucose in the urine, a tripling of blood glucose level, weight loss and an increase in glycated haemoglobin levels. Three months after diabetes onset, the electroretinogram b/a wave amplitude ratio was decreased at the highest light intensities and oscillatory potentials were delayed. The retinal fundus and vessels remained unchanged. No cell apoptosis was detected in vertical and horizontal sections of the retina by TUNEL or immunocytochemistry for the active caspase 3. No increase in GFAP-immunostaining indicative of a glial reaction was observed in Mü ller glial cells. By contrast, changes in the morphology of microglial cells were observed, with marked shortening of the dendrites. Thus, the microglial reaction occurs very early in progression to diabetic retinopathy, at about the same time as early electroretinographic modifications. The absence of apoptotic cells, contrasting with previous results in mice with streptozotocininduced diabetes, is consistent with insulin neuroprotection.
Introduction
Diabetic retinopathy (DR) is a common complication of diabetes that can lead to legally recognised blindness. This condition has been extensively studied but its pathophysiology remains poorly understood. DR is classically considered to be a microangiopathy because microaneurysms and the proliferation of new vessels are observed, together with a breakdown of the blood retinal barrier (BRB). The BRB is located at the junctions between endothelial cells in the capillaries. Its normal function is regulating the movement of molecules into and out of the retina. BRB breakdown is routinely identified in patients with DR in clinical practice, by fluorescein angiography, in which the abnormal leakage of fluorescein from the capillaries is observed (Davis, 1992) . These vascular changes may result from biochemical disorders, such as activation of the polyol and b-kinase pathways, and the production of glycated products and 0042-6989/$ -see front matter Ó 2006 Elsevier Ltd. All rights reserved. doi:10.1016/j.visres. 2006.11.017 reactive oxidative species due to an increase in serum glucose concentration (Ciulla, Amador, & Zinman, 2003) .
Retinal cell degeneration and blindness may result from these vascular changes and subsequent retinal ischaemia.
However, several recent studies have suggested that neurodegenerative events may precede the vascular changes. Indeed, changes in retinal function have been reported in humans and animals before the detection of retinal vascular lesion in the form of BRB rupture or microaneurysms. In diabetic patients, colour vision and contrast sensitivity may deteriorate without detectable clinical symptoms of DR (Ewing, Deary, Strachan, & Frier, 1998) . Electroretinograms (ERG) show very early changes in oscillatory potentials (OP) and changes are also observed on multifocal ERG (Bresnick & Palta, 1987; Fortune, Schneck, & Adams, 1999; Tzekov & Arden, 1999; Yoshida, Kojima, Ogasawara, & Ishiko, 1991) . Histologically, neuronal apoptosis has been observed in ganglion cells before any change could be detected in the retinal vascular system . This degeneration is associated with glial reactions in Müller cells, generally observed following the appearance of retinal lesions (Abu-El-Asrar, Dralands, Missotten, Al-Jadaan, & Geboes, 2004) .
Proliferative diabetic retinopathy has rarely been described in diabetic animal models, although neovascularisation has been described in a few transgenic animals (Lai et al., 2005; Ruberte et al., 2004; Yamada, Yamada, Higuchi, & Matsumura, 2005) . Changes of various magnitudes have been reported on ERG: increases in OP latencies, and decreases in OP amplitudes, a-and b-waves (Ewing et al., 1998; Hancock & Kraft, 2004; Li, Zemel, Miller, & Perlman, 2002; Lowitt, Malone, Salem, Kozak, & Orfalian, 1993; Sakai, Tani, Shirasawa, Shirao, & Kawasaki, 1995) . Neuronal apoptosis has been described in the ganglion cell layer in various diabetic animal models (Agardh, Bruun, & Agardh, 2001; Barber et al., 1998; Martin, Roon, Van Ells, Ganapathy, & Smith, 2004; Ning et al., 2004) . Neuronal degeneration has also been detected in other retinal layers in some models (Agardh et al., 2001; Ning et al., 2004) . This degenerative process has been attributed to the glial reaction of Mü ller cells, as in diabetic humans (Agardh et al., 2001; Asnaghi, Gerhardinger, Hoehn, Adeboje, & Lorenzi, 2003; Li et al., 2002; Lieth et al., 1998; RunggerBrandle, Dosso, & Leuenberger, 2000) , or to microglial cell activation in some cases (Barber et al., 2005; RunggerBrandle et al., 2000; Zeng, Ng, & Ling, 2000) . However, these neuroglial reactions are not observed in all animal models of DR (Agardh et al., 2001; Asnaghi et al., 2003; Barber et al., 2005 Barber et al., , 1998 Li et al., 2002; Lieth et al., 1998; Martin et al., 2004; Ning et al., 2004; Rungger-Brandle et al., 2000) . In particular, neuronal apoptosis was first described in rats with streptozotocin-induced diabetes , but is not systematically observed in mice with streptozotocin-induced diabetes (Asnaghi et al., 2003; Martin et al., 2004) .
In this study, we assessed BRB permeability and retinal cell activity in vivo, in mice with alloxan-induced diabetes, a classical animal model of diabetes in which DR has not yet been investigated. Alloxan and STZ are both diabetogenic agents with cytotoxic effects on pancreatic b-cells resulting from the production of reactive oxygen species. Alloxan generates oxidative stress conditions, with a simultaneous massive increase in cytosolic calcium concentration, whereas STZ induces DNA alkylation (Szkudelski, 2001) . At the first sign of functional changes in Alloxan-induced mice, we looked for neuroglial reactions on vertical and horizontal retinal sections. We report here that changes in microglial cell morphology are the first detectable cellular modifications occurring in mice with alloxan-induced diabetes, apparently preceding neuronal apoptosis and increases in blood barrier permeability in this model.
Materials and methods

Animals and experimental diabetes induction
We used twenty C57/Bl6 male mice, which were handled according to the principles of the ARVO statement for the use of animals in ophthalmic and vision research. The mice were maintained on a standard diet, with water supplied ad libitum, under a 12-h light/12-h dark cycle. Diabetes was induced by a single injection of Alloxan (75 mg/kg) into the tail vein, as described by Larger, Becourt, Bach, and Boitard (1995) . Animals were 10 weeks old and weighed around 25 g at the time of injection. Nine mice received injections, the others being used as controls. Diabetic mice received a daily subcutaneous injection of three international units of insulin (Umuline Zinc Ò , Lilly Laboratories, France), in the morning (9 a.m.). Insulin was administered to keep the animals alive during the study period, because a few mice with alloxan-induced diabetes had previously been reared without treatment, but they had survived for no more than two weeks.
Glucose levels
Animals were weighed once per week. We checked for the presence of glucose in the urine twice during the first week after injection (urine glucose test strips, Roche Diagnostics, France). Blood glucose levels were determined once per week for the three months of the study and just before the mice were killed. Blood samples were obtained from the lateral vein of the tail (blood glucose meter and OneTouch Ultra test strips, Lifescan, France).
Glycated haemoglobin determinations
Just before the animals were killed, blood samples from the right retroorbital venous sinus were collected into calcium ethylenediaminotetra-acetic acid (EDTA). Glycated haemoglobin levels were determined automatically, by high-performance liquid chromatography, as described by Ou and Rognerud (1993) . Briefly, we diluted 10 lL of blood in a hypotonic cell lysis solution (0.1% Brij, Sigma). Haemoglobins were then separated on a porous silica column containing polyaspartic acid (Poly CatA, Poly LC, Houston, USA). Various ionic gradients were obtained by mixing two buffer solutions (20 mM bis-Tris, 2 nM KCN, pH 5.8 and 20 mM bis-Tris, 2 nM KCN, 75 mM trisodium citrate, pH 5.8). These gradients were used to separate the haemoglobins, which were detected by spectroscopy at 418 nm.
Ocular examination, funduscopy and fluorescein angiographs
Fundus examinations and angiographs were performed on all mice, 15 days, 1 month and 3 months after the pharmacological induction of diabetes. Cornea, eye lens and fundus were examined with a biomicroscope (BQ, Haag-Streit, Germany) and a 90-dioptre lens (Volk, USA). Photographs of the eye fundus and angiographs were obtained with a scanning laser ophthalmoscope (SLO) (HRA, Heidelberg, Germany). Retinal angiography was carried out after the intraperitoneal injection of 25% fluorescein in 0.9% NaCl. Mouse pupils were dilated by the ocular instillation of tropicamide eye drops (0.5%). Fundus images were obtained for each eye before, 1 and 5 min after the fluorescein injection.
Retinal electrophysiology
Electroretinograms (ERG) were obtained from all animals, 15 days, 1 month and 3 months after diabetes induction. Animals were acclimatised to the dark for 12 h before the recording. They were anaesthetised by intraperitoneal injection (10 ll/g) of a mixture of ketamine (10%) and xylazine (7.5%) in 0.9% NaCl. Corneas were anaesthetised with oxybuprocaine chlorhydrate (0.4%) and the pupil was dilated with tropicamide (0.5%). Each animal was placed on a heating pad, and the eyelids were retracted to keep the eye open during the recording. A gold electrode was placed on the cornea with a drop of methylcellulose and the neutral and reference electrodes were placed on the tail and head of the animal, respectively. Light stimulation was delivered via a Ganzfeld light source, with flash intensities from 10 À4 to 25 cd s m
À2
. Responses were amplified, high-and low-pass-filtered (1-300 Hz) and digitised (Multiliner Vision, Toennies/Jaeger, Hoechberg, Germany). Oscillatory potentials (OP) were isolated for a light stimulus of 3 cd s m À2 by filtering the responses with a high-pass filter at 100 Hz and a low-pass filter at 300 Hz. The amplitudes and latencies of the ERG a-and b-waves were measured at the maximum negative and positive peaks of the recordings with respect to the baseline before stimulation. As recommended by the ISCEV (International Society for Clinical Electrophysiology of Vision), OP amplitudes were measured from the negative peak to the next positive peak whereas OP latencies were measured at the positive peaks. We summed OP amplitudes (Sampl) and latencies (Slat) for the first 5 OP because these parameters provide information about inner retinal cell function (amacrine cells) and were found to be modified in other diabetic animal models (Hancock & Kraft, 2004; Hotta et al., 1997) and in diabetic patients (Bresnick & Palta, 1987; Yoshida et al., 1991) .
Cell labelling
Animals were killed three months after diabetes induction. The left eye of each animal was enucleated for the labelling of cells on vertical retinal sections, whereas the right eye was dissected for the preparation of a flatmounted retina. Eye cups and retina were fixed overnight in 4% paraformaldehyde (PAF) at 4°C. A few flat-mounted retina (from one control and two diabetic mice) were embedded in orbithine carbamyl transferase (OCT) medium and cut into 40 lm-thick horizontal retinal sections. Entire retinas were stained for GFAP as described by Rungger-Brandle et al. (2000) , by incubation with the polyclonal anti-GFAP antibody (2.5 days, 4°C), followed by washing and incubation with the secondary antibody (1.5 days, 4°C). Retinae were incubated with antibodies in a permeabilising solution containing 1% Triton X-100 in phosphate-buffered saline (PBS). Vertical retinal sections were cut from eye cups embedded in OCT medium after cryoprotection in various sucrose solutions. Vertical sections were permeabilised by incubation for 1 h at 37°C with 0.5% Triton X-100 in a solution containing 1% bovine serum albumin (BSA) and 0.05% Tween 20 in PBS. Sections were incubated overnight at 4°C with primary antibodies diluted in permeabilising solution. The primary antibodies used were rabbit anti-GFAP (1/200, Dako, USA) and rabbit anti-phosphotyrosine (1/500, Zymed, USA) antibodies. Sections were washed several times in PBS and then incubated for 1 h at room temperature with the secondary antibody in permeabilising solution supplemented with 4 0 ,6-diamidino-2-phenylindole (DAPI) for nuclear staining (1/500, Sigma). The secondary antibody used was an Alexa fluor 488-or 594-conjugated goat anti-rabbit antibody (1/500, Molecular Probes, USA).
Neuronal apoptosis was investigated by terminal UTP nick-end labelling (TUNEL) coupled with fluorescein (TUNEL-FITC detection kit; Roche Diagnostics, France). Vertical sections (5-8 per retina) and horizontal sections (6 per eye) of retina were permeabilised by incubation for 5 min with 0.1% Triton X-100 in PBS. They were then stained by incubation with 4 0 ,6-diamidino-2-phenylindole (DAPI) for 5 min, and incubated with the kit solution for 1 h at 37°C.
Cell quantification
All specimens were viewed with a fluorescence microscope (Leica DM5000B, Germany) equipped with a digital camera (Coolsnap fx, Photometrix, Roper Scientific, USA) linked to a computer running image analysis software (Metavue 6.2R4, Universal Imaging Corp, USA). Digital images were acquired using identical settings in all cases. Microglial cells were counted and the length of their dendrites was determined on two different retinal sections including the optic nerve for each animal. Dendrites were measured with Metavue software.
Statistical analysis
Statistical comparisons were made by unpaired t-tests when possible, and by non-parametric Mann-Whitney U-tests otherwise. Statistical analysis was carried out with Statview 5.0 (SAS Institute Inc., USA). Significance tests were performed with (p = 0.05) taken as the threshold for significance.
Results
Diabetes follow-up
Following the injection of alloxan, the induction of diabetes was confirmed based on weight stagnation, polydipsia and polyuria in mice (Fig. 1) . The day after alloxan injection, glucose was detected in the urine and blood glucose levels at least doubled in injected mice. The blood glucose levels ranged from 5.89 to 13.68 mM in control animals and from 19.68 to 33.36 mM in diabetic mice. Blood glucose levels remained three times higher in diabetic than in control animals throughout the three-month study period and the weight gain of these animals was reduced by approximately 50% (Fig. 1) . Three months after the diabetes induction, glycated haemoglobin levels were 2.72% (±0.06, n = 9, SEM) in control mice and 6.54% (±0.82, n = 5, SEM) in diabetic animals. Thus, despite the continuous insulin treatment, the diabetic mice displayed chronic hyperglycaemia.
No vascular lesion
We evaluated the integrity of the blood retinal barrier, by examining diabetic and control animals by fluorescein angiography with a scanning laser ophthalmoscope. No haemorrhage, microaneurism or proliferation of new vessels was detected. Fig. 2 shows fluorescein angiograms for control and diabetic animals. We assessed the diffusion of this dye out of the capillary network by analysing angiograms taken at different time points after fluorescein injection, because fluorescein diffusion into the retinal tissue provide evidence for the breakdown of the internal BRB (Rakoczy et al., 2003) . However, no fluorescein diffusion into the retinal tissue was detected and the morphology and density of the retinal capillary network remained unchanged in diabetic and control mice throughout the entire study (Fig. 2 ). These observations suggest that the BRB was not ruptured during the three months of the experiment in mice with alloxan-induced diabetes.
Functional changes
We investigated the possible effects of diabetes on neuronal cell activity in our model, by recording electroretinograms at various time points after the induction of diabetes. We checked that the cornea and ocular lens were clear before each recording, because cataracts are often observed in diabetic animals. No statistically significant change in ERG was detected one month after diabetes induction. After three months, the amplitudes and latencies of the ERG a-and b-waves remained unchanged, but a significant decrease in the b-wave/a-wave amplitude ratio (b/ a) was observed for light intensities of 10 and 25 cd s m À2 (t test, p = 0.014 and 0.018 respectively). The sum of OP latencies was also higher in diabetic mice (n = 5, t test, p = 0.034) than in control mice (n = 9) (Fig. 3, Table 1 ). These observations suggest that three months of diabetes led to changes in neuronal cell activity.
Absence of neural apoptosis
In diabetic animal models, neuronal apoptosis has been reported as early as one month after diabetes induction . We therefore investigated the distribution of apoptotic cells in vertical and horizontal retinal sections, using TUNEL and cleaved caspase 3 detection. Even three months after the induction of diabetes, no apoptotic cells were detected with either of the cell death markers. For example, Fig. 4A and B shows the absence of TUNEL staining on vertical retinal sections from control animals and diabetic mice three months after diabetes induction.
The efficacy of our labelling technique was checked by staining retinal sections from an rd (retinal degeneration) mouse by TUNEL. As expected, in this animal presenting photoreceptor degeneration, several TUNEL-positive apoptotic cells were detected in the outer nuclear layer (Fig. 4C, arrows) . TUNEL was also performed on horizontal sections, because only a few retinal ganglion cells are present in vertical sections and these cells have been reported to undergo degeneration early in progression to DR in diabetic patients and in rats with streptozotocin-induced diabetes . No TUNEL-positive cells were detected on horizontal sections containing large numbers of retinal ganglion cells (data not shown). Despite the observed change in retinal cell activity, no retinal cell apoptosis was detected three months after the induction of diabetes with alloxan.
Absence of macroglial reaction
As a glial reaction has been described in diabetic animal models and human patients (Agardh et al., 2001; Hancock & Kraft, 2004; Li et al., 2002; Lieth et al., 1998; RunggerBrandle et al., 2000; Sakai et al., 1995) , we labelled vertical retinal sections with an anti-GFAP antibody. In control animals, this antibody labelled astrocytes in the ganglion cell layer (Fig. 4D) . Three months after the induction of diabetes, no abnormal glial reaction was observed in diabetic mouse retina. A few Mü ller cells were stained in the inner retina (Fig. 4E, arrow) , but such staining was also observed in a few control retinas. We stained a retinal section from an rd mouse with the anti-GFAP antibody, to obtain information about the nature of reactive glial cells. In this mouse, the anti-GFAP antibody strongly labelled many glial cell processes extending from the outer plexiform layer to the inner limiting membrane (Fig. 4F, arrow) . We investigated possible changes in morphology in these labelled astrocytes by staining the whole retina for GFAP. In diabetic animals, the morphology of the GFAP-positive astrocytes was normal on flat-mounted retina ( Fig. 4G and  H) . This examination demonstrated the absence of a macroglial reaction in mice with alloxan-induced diabetes, three months after diabetes induction.
Microglial changes
Microglial cells in the ganglion cell layer, the inner plexiform layer and the inner nuclear layer were visualised by specific staining with an anti-phosphotyrosine antibody (Fig. 5) . The specificity of immunolabelling was demonstrated on a vertical section of retina from a mouse strain in which the gene encoding the chemokine receptor CX3CR1 was replaced by the gene encoding enhanced green fluorescent protein (EGFP) (Jung et al., 2000) . In these animals, brain and retinal microglial cells, which would normally express CX3CR1, become EGFP-positive. These EGFP-positive retinal microglial cells were immunolabelled with the anti-phosphotyrosine antibody (Fig. 5A-C) . In vertical retinal sections, microglial cell nuclei and processes were clearly identified and quantified (D-F) GFAP expression in retinal sections of diabetic mice (E) was no stronger than that in control animals (D), whereas stronger staining was observed with sections from rd mice (F). (G and H) GFAP-positive astrocytes displayed no morphological alterations on flat-mounted retinas from control animals (G) and diabetic mice (H). Scale bars represent 10 lm. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer. in the inner nuclear layer (INL), inner plexiform layer (IPL) and ganglion cell layer (GCL). Diabetic and control animals had similar numbers of phosphotyrosine-positive microglial cells (Fig. 5F ), but the cell bodies of these cells seemed to be larger in diabetic animals, with thicker proximal processes and shorter dendrites ( Fig. 5D-E) . The cumulative length of microglial dendrites was determined on complete sections including the optic nerve ( Fig. 5G and H), and was found to differ significantly between diabetic and control animals (Fig. 5I , t test, p = 0.01). As microglial cells are known to display a change in morphology, including dendrite contraction, in the early stages of activation, these observations suggest that microglial cells were activated three months after the onset of diabetes in mice with alloxan-induced diabetes.
Discussion
This study on mice with alloxan-induced diabetes showed that changes to oscillatory potentials and ERG b/a amplitude wave ratio first became detectable three months after the onset of diabetes. No change in blood vessel permeability was detected in vivo by fluorescein angiography carried out with a scanning laser ophthalmoscope. No ganglion cell apoptosis or macroglial reaction was detected, but changes in microglial cells were observed, with a decrease in the length of microglial cell processes, which is known to occur early in microglial activation. Insulin treatment was insufficient to regulate blood glucose levels, but may have protected against neuronal apoptosis.
The sequence of events in the retina following the induction of diabetes
In diabetic patients, OPs provide the first sign of retinal alteration, as their amplitude decreases and their latency increases even at a pre-retinopathy stage characterised by an absence of detectable vascular changes on funduscopy (Shirao & Kawasaki, 1998) . Other ERG changes have also been observed, including a change in ERG pattern (Caputo et al., 1990) , scotopic and photopic b-wave alterations (Holopigian, Seiple, Lorenzo, & Carr, 1992 ) and a specific reduction of S-cone ERG (Yamamoto, Kamiyama, Nitta, Yamada, & Hayasaka, 1996) . Changes in OP latencies and amplitudes have also been described in various animal models (Li et al., 2002; Sakai et al., 1995; Segawa, Hirata, Fujimori, & Okada, 1988) . In rats with STZ-induced diabetes, these OP changes are detected as early as two weeks after diabetes induction (Li et al., 2002; Sakai et al., 1995) . Other changes in ERG responses, such decreases in b-wave magnitude, have also been observed in these animal models (Li et al., 2002) . In our mice with alloxan-induced diabetes, no significant changes were detected in ERG a-and b-waves, but changes in the b/a wave amplitude ratio were statistically significant three months after the onset of diabetes. Indeed, this ratio could be used to normalise ERG measurements between mice. However, the variability of this measure in control animals at the various time points studied (Table 1) limits the value of the difference observed at three months. By contrast, OP latencies steadily increased over the first three months, providing evidence for the importance of the statistically significant increase in OP latency reported at 3 months. Similar increases in OP latency have been reported for streptozotocin-treated rats after five weeks of diabetes (Li et al., 2002; Sakai et al., 1995) and in diabetic patients with and without retinopathy (Bresnick & Palta, 1987; Yoshida et al., 1991) . The presence of such increases in OP latency in diabetic patients without retinopathy and in our alloxan-treated mice is consistent with the notion that this change is a very early marker of diabetes-induced retinal changes. These ERG changes are consistent with the suggested changes in the GABA-ergic system or with dysfunction of the inner retinal vasculature (Hanitzsch, Kuppers, & Flade, 2004; Ishikawa, Ishiguro, & Tamai, 1996a; Ishikawa, Ishiguro, & Tamai, 1996b; Shirao & Kawasaki, 1998; Wachtmeister, 1998) .
In diabetic patients and animals, retinal cell apoptosis in the various retinal layers has been described as an early event, preceding vascular alterations (Asnaghi et al., 2003; Barber et al., 1998; Martin et al., 2004; Ning et al., 2004; Park et al., 2003) . In animal models, this cell death, detected by both TUNEL and immunolabelling for active caspase-3, has generally been detected in the ganglion cell layer one month after the induction of diabetes, but it may also occur earlier, after as little as two weeks (Ning et al., 2004) . Retinal cell death has also been observed in the photoreceptor layer and the inner nuclear layer, but during a later phase of the disease (Ning et al., 2004; Park et al., 2003) . In mice with STZ-induced diabetes, Asnaghi reported no increase in the number of apoptotic cells after 10 and 24 weeks of diabetes, whereas Martin reported such retinal apoptosis at 2, 6 and 12 weeks (Asnaghi et al., 2003; Martin et al., 2004) . In mice with alloxan-induced diabetes, no cell death was detected in any cell layer after three months of diabetes, even if horizontal sections were used so that large numbers of ganglion cells could be studied at a glance. These results indicate that the early ERG changes are not a consequence of retinal cell death.
Several studies have reported that ERG modifications and ganglion cell apoptosis are followed by a glial reaction in diabetic patients and animal models (Agardh et al., 2001; Hancock & Kraft, 2004; Li et al., 2002; Lieth et al., 1998; Rungger-Brandle et al., 2000; Sakai et al., 1995) . In rats with STZ-induced diabetes, the glial reaction appeared after 6-15 weeks of diabetes (Li et al., 2002; Lieth et al., 1998) . In mice with alloxan-induced diabetes, ERG modifications appeared only after 3 months of diabetes and no glial reaction, as assessed by GFAP labelling, could be detected. Further studies should determine whether this glial reaction and ganglion cell death occur even later in this model.
Microglial cells are also activated in rats with STZ-induced diabetes (Rungger-Brandle et al., 2000; Zeng et al., 2000) and in Ins2 Atika mice (Barber et al., 2005) . In rats, this activation is demonstrated by the hypertrophy of microglial cells after 1 month of diabetes, the number of cells increased after 4 months these cells migrated into the outer nuclear layer after 14 to 16 months (Zeng et al., 2000) . Rungger-Brandle et al. (2000) detected an increase in the number of microglial cells as early as 1 month after diabetes induction, before the increase in GFAP expression. Barber found swollen and retracted microglial cell processes in Ins2 Atika mice (Barber et al., 2005) , as observed in our mice with alloxan-induced diabetes. No increase in the number of retinal microglial cells was detected in mice with alloxan-induced diabetes, but we did observe a change in the morphology of these cells, as described above. These changes in the morphology of microglial cells are known to be associated with the microglial ''alert'' activation stage (Raivich et al., 1999) . Our findings suggest that microglial cells may be activated in the diabetic mouse retina before ganglion cell death and the subsequent macroglial reaction. These observations are consistent with findings for Ins2 Atika mice showing microglial activation but no increase in GFAP expression by Mü ller cells (Barber et al., 2005) . Microglial cell activation was correlated with the ERG changes observed in our study, and may trigger the ganglion cell death reported in other diabetic animal models. This sequence of events is supported by the neuroprotection conferred by the anti-inflammatory drug, minocycline, in animals with streptozotocin-induced diabetes . The sequence of retinal modifications early in DR can therefore be deduced from the combined results of all these studies: microglial activation may initially be associated with OP changes and ERG b/a amplitude ratio reduction; these modifications are followed by ganglion cell apoptosis and subsequent macroglial reaction.
Differences between diabetic animal models
There seem to be discrepancies in the sequence of cellular events in the various diabetic animal models described. For example, the permeability of the BRB increases as early as three to ten days after the induction of diabetes in rats by streptozotocin injection (Diani et al., 1987) . In Ins2 Atika mice, the BRB was broken down only after 12 weeks of diabetes, and in our mice with alloxan-induced diabetes, even this period was not long enough. These differences may result from differences in the techniques used to study the BRB, or from differences in the animal strains and species (as supported by the findings of Zhang et al., 2005) or in the origin of the diabetes, with the BRB seeming to be much more resistant in diabetic mice than in diabetic rats.
Another main difference between these animal models concerns the induction of neuronal apoptosis, principally in the ganglion cell layer. Ganglion cell apoptosis has been reported to occur as early as 15 days after the onset of diabetes in mice with STZ-induced diabetes (Martin et al., 2004) and at 1 month in KKAY spontaneous diabetic mice, which also have a triglyceride metabolism disorder (Ning et al., 2004) . In the Ins2 atika mice, apoptotic cells were detected as four weeks after the onset of diabetes and the number of cell bodies in the ganglion cell layer was found to be smaller than in the control after 22 weeks of diabetes (Barber et al., 2005) . By contrast, no ganglion cell apoptosis was detected in our model of mice with alloxan-induced diabetes, even after three months. Alloxan and STZ both trigger pancreatic b-cell necrosis and diabetes: alloxan does so by creating an oxidative stress whereas STZ induces DNA alkylation (Szkudelski, 2001) . No data are available concerning the relative toxicities of these two drugs to the mouse retina. However, the reported STZ-induced ganglion cell death is unlikely to be due to a direct toxic effect on the retina, for two reasons. Firstly, Asnaghi et al. (2003) reported an absence of glial reactions and ganglion cell apoptosis in mice with STZ-induced diabetes, three months after the induction of diabetes (Asnaghi et al., 2003) . Secondly, insulin injection can reduce the number of apoptotic ganglion cells in rats with STZ-induced diabetes .
The absence of ganglion cell apoptosis in our study and in that by Asnaghi et al. (2003) may result from neuroprotective effects of insulin. In both these studies, the diabetic mice received regular insulin injections, whereas, in other studies reporting ganglion cell apoptosis, the diabetic mice received no insulin (Asnaghi et al., 2003; Barber et al., 1998; Martin et al., 2004; Ning et al., 2004; Park et al., 2003) . Insulin is classically administered to normalise blood glucose levels, to prevent complications due to hyperglycaemia. In rats with STZ-induced diabetes, insulin injections can restore normal glycaemia and limit the number of apoptotic ganglion cells . In our study, the ganglion cell survival cannot be attributed to insulinmediated control over glycaemia, because blood glucose levels were not normalised by insulin injections during the study period. Insulin was administered to prevent the rapid death of untreated animals. Similarly, insulin has been shown to mediate the neuroprotection of ganglion cells in rats with STZ-induced diabetes, despite incomplete control of hyperglycaemia (Asnaghi et al., 2003) . Insulin neuroprotection has also been reported in cultured R28 retinal neurons, following serum deprivation (Wu et al., 2004) . The injection of insulin into mice with alloxan-or STZ-induced diabetes may, thus, also provide neuroprotection for ganglion cells.
Conclusion
In summary, we report here the absence of neuronal apoptosis three months after the induction of diabetes by alloxan injection in mice. By contrast, the microglial changes and electroretinographic alterations reported in other models of DR were observed. In future studies, we will investigate whether this early inflammatory response can trigger ganglion cell death and the macroglial reaction in animals with DR.
